| 05.22.25 | Sanofi inks $470M Vigil buy for Alzheimer's asset; Gilead pays $10M for Hookipa HBV, HIV programs

Laden...

1 maand 30 dagen geleden

Html
Tekst

Meet Premier at ASCO – A Faster Path to Approval Starts Here

Discover how our oncology-focused clinical development solutions help you move from milestone to milestone with speed and precision. Let’s talk smarter trials. Request more information.

Today’s Big News

May 22, 2025

Sanofi inks $470M Vigil buyout, brushing off rivals' failures to join Novartis in Alzheimer's race

Gilead pays partner Hookipa $10M to take over HBV, HIV therapeutic vaccine programs

Eikon blames US funding cuts for 15% staff reduction centered on research tools business

France invests €1.3M into novel mRNA project led by OSE Immunotherapeutics

Scientists ID potential drug target to prevent cancer from spreading to bones

Zentiva inks €220M deal to commercialize AstraZeneca GI cast-off in Europe

Finance your equipment with NFS Capital and keep your capital focused on critical priorities like research, commercialization, hiring, and growth. NFS provides flexible equipment financing for biotech and life sciences companies. Learn more here.

Featured

Sanofi inks $470M Vigil buyout, brushing off rivals' failures to join Novartis in Alzheimer's race

By Nick Paul Taylor

Sanofi’s 11 months watching over Vigil Neuroscience have led to a $470 million buyout. With the biotech into the last year of its cash runway, Sanofi has swept in to secure a small molecule that could challenge Novartis for the Alzheimer’s disease market.

Gilead pays partner Hookipa $10M to take over HBV, HIV therapeutic vaccine programs

By James Waldron

Gilead is paying $10 million for sole ownership of arenaviral immunotherapies for hepatitis B (HBV) and HIV resulting from the company’s long-running collaboration with Hookipa Pharma.

Eikon blames US funding cuts for 15% staff reduction centered on research tools business

By James Waldron

Only three months after banking an eye-popping $350 million series D round, Eikon Therapeutics is blaming government funding cuts for its decision to lay off 15% of its employees.

Built for the Journey: How Bridge Bank Builds Long-Term Banking Relationships in Life Sciences

Sponsored by Bridge Bank, a division of Western Alliance Bank, Member FDIC

Here’s how experienced banking partnerships create value beyond traditional lending and why industry-specific expertise matters in navigating the complex life sciences landscape.


A message from Bora Pharmaceuticals

France invests €1.3M into novel mRNA project led by OSE Immunotherapeutics

By Gabrielle Masson

French biotech OSE Immunotherapeutics is taking charge of a new project aimed at fast-tracking nanodrug development and creating new mRNA therapeutics, with 1.3 million euros ($1.47 million) in support from the French government.

De-Risking Tech Transfer: A Smarter Path to Faster, More Reliable Outsourcing Outcomes

Scientists ID potential drug target to prevent cancer from spreading to bones

By Darren Incorvaia

A team of scientists has harnessed CRISPR technology to identify a protein that helps cancers spread to bone tissue, opening the door for potential therapies to prevent the common and painful disease progression.

Innovative Breakthrough in Cancer Testing Developed in Ohio

Sponsored by Ohio Discovery Corridor

Cleveland Diagnostics redefines cancer detection with new technology developed at the Cleveland Clinic in the heart of the Ohio Discovery Corridor.

Zentiva inks €220M deal to commercialize AstraZeneca GI cast-off in Europe

By Darren Incorvaia

Former Sanofi subsidiary Zentiva has bought in to an ex-AstraZeneca asset for gastric-acid-related diseases, forging a 220 million euro alliance with Cinclus Pharma to commercialize and manufacture linaprazan glurate in Europe.

Clinical trial diversity nonprofit launches with FDA, Big Pharma vets on its board

By Darren Incorvaia

After a two-year pilot period, Equitable Breakthroughs in Medicine Development has officially launched a nonprofit meant to expand access to clinical trials.

FDA advisors unanimously snub Pfizer's Talzenna in broader prostate cancer population

By Fraiser Kansteiner

Eight outside experts on the FDA’s Oncologic Drugs Advisory Committee delivered a unanimous ‘No’ vote on the question of whether Pfizer’s PARP inhibitor Talzenna has a favorable benefit-risk profile in metastatic castration-resistant prostate cancer patients without homologous recombination repair gene mutations.

New Evernorth program to cap out-of-pocket costs for Wegovy, Zepbound at $200

By Paige Minemyer

Cigna's Evernorth is rolling out a new pharmacy benefit management program that caps members' monthly cost for key GLP-1 drugs.

After WHO loses its top donor in US, Novo Nordisk Foundation and China step up with large contributions

By Kevin Dunleavy

With the withdrawal of the U.S. from the World Health Organization, the United Nations-backed agency has lost its top donor. Helping compensate for the funding shortfall is the Novo Nordisk Foundation, which has pledged up to 380 million Danish kroner ($58 million) from this year to 2028. China also has stepped up, pledging $500 million over the next five years.

Fierce podcasts

Don’t miss an episode

A Fierce breakdown of the 'most favored nation' executive order

This week on "The Top Line," Fierce Pharma breaks down President Donald Trump’s executive order targeting drug prices and what it could mean for the industry as broader policy shifts unfold.

A pulse check on AI adoption in healthcare

Angela Hwang on her pivot from Big Pharma to biotech

Webinar: Advancing Precision Oncology

Thursday, May 29, 2025 | 11am ET / 8am PT

While the use of precision therapies continues to expand, precision oncology drug development is facing increasing costs and complexity. It is more important than ever to implement strategies and solutions for maximizing efficiencies throughout the drug development process. Join us to learn more.

Resources

Whitepaper

Upcoming Fierce Events

8-11Sep

Fierce Pharma WeekPhiladelphia, PA

10Sep

Fierce Pharma Marketing AwardsPhiladelphia, PA

7-9Oct

Fierce Biotech WeekBoston, MA

12-13Nov

Diversity, Equity & Inclusion ForumFree Virtual Event

20Nov

Fierce 50 Awards GalaThe Lighthouse at Pier 61 in New York City

View all events

This email was sent to newsletter@newslettercollector.com as part of the Fierce Biotech email list.

Deel deze op

Laden...

Andere nieuwsbrieven van Fiercebiotech.com

| 06.21.25 | Employers rethinking benefit strategies; Providence to cut 600 in restructure Fiercebiotech.com
15 uren geleden
| 06.20.25 | FDA reportedly sidelines top cell and gene official; ACIP meeting changes echo MAHA playbook Fiercebiotech.com
Gisteren om 18:06
How to Ethically Use Real-World Data in Oncology Trials Fiercebiotech.com
Gisteren om 17:35

Meer nieuwsbrieven van Fiercebiotech.com

Laden...

Meet Premier at ASCO – A Faster Path to Approval Starts Here

Today’s Big News

Featured

Sanofi inks $470M Vigil buyout, brushing off rivals' failures to join Novartis in Alzheimer's race

Top Stories

Gilead pays partner Hookipa $10M to take over HBV, HIV therapeutic vaccine programs

Eikon blames US funding cuts for 15% staff reduction centered on research tools business

Built for the Journey: How Bridge Bank Builds Long-Term Banking Relationships in Life Sciences

France invests €1.3M into novel mRNA project led by OSE Immunotherapeutics

De-Risking Tech Transfer: A Smarter Path to Faster, More Reliable Outsourcing Outcomes

Scientists ID potential drug target to prevent cancer from spreading to bones

Innovative Breakthrough in Cancer Testing Developed in Ohio

Zentiva inks €220M deal to commercialize AstraZeneca GI cast-off in Europe

Clinical trial diversity nonprofit launches with FDA, Big Pharma vets on its board

FDA advisors unanimously snub Pfizer's Talzenna in broader prostate cancer population

New Evernorth program to cap out-of-pocket costs for Wegovy, Zepbound at $200

After WHO loses its top donor in US, Novo Nordisk Foundation and China step up with large contributions

Don’t miss an episode

A Fierce breakdown of the 'most favored nation' executive order

A pulse check on AI adoption in healthcare

Angela Hwang on her pivot from Big Pharma to biotech

Webinar: Advancing Precision Oncology

Resources

Accelerating Clinical Trial Excellence: A Seamless IRB & IBC Collaboration

SpyLock Technology: A cutting-Edge Solution for Rapid Bispecific Antibody Screening

Best Practice Medical Affairs Organization Study Report

Upcoming Fierce Events

| 05.22.25 | Sanofi inks $470M Vigil buy for Alzheimer's asset; Gilead pays $10M for Hookipa HBV, HIV programs

Today’s Big News

Featured

Top Stories

Don’t miss an episode

Resources

Upcoming Fierce Events

Deel deze op

Andere nieuwsbrieven van Fiercebiotech.com

Gerelateerde nieuwsbrieven